genetics

  • Bio
    WuXi NextCODE aims for the genomics database “gold standard” with new $240 million

    WuXi NextCODE aims for the genomics database “gold standard” with new $240 million

    A lot of money is being poured into genomics lately, including the genomic information company WuXi NextCODE (WXNC), which just announced it has closed on $240 million in Series B financing, led by Sequoia. We tend to hear very little about this company in the tech industry but Chinese tech billionaire Jack Ma is one of its many backers and WXNC is counted among the largest genetic… Read More

  • Bio
    EverlyWell rolls out three new DNA-based products for food sensitivity, metabolism and breast milk

    EverlyWell rolls out three new DNA-based products for food sensitivity, metabolism and breast milk

    There’s a lot going on in commercial DNA testing these days beyond what eye color you have or where your mitochondria comes from, and at-home lab testing startup EverlyWell hopes to cash in. The startup launched three new products today, based on your DNA to help get it there, including a food sensitivity test, DNA factors for your metabolism and breast milk DHA. Read More

  • Bio
    Scientists have eliminated HIV in mice using CRISPR

    Scientists have eliminated HIV in mice using CRISPR

    An important breakthrough has been made in the eradication of AIDs. Scientists have found they can successfully snip out the HIV virus from mouse cells using CRISPR/Cas9 technology. Read More

  • Bio
    Early cancer detection startup GRAIL closes on $900 million in Series B funding

    Early cancer detection startup GRAIL closes on $900 million in Series B funding

    Life sciences startups need a whole lot more cash than most and that’s certainly true for GRAIL, a cancer detection startup trying to figure out a way to find the “emperor of all maladies” much earlier through blood testing technology. The startup, which spun out of genomics company Illumina announced it has closed a whopping $900 million in Series B funding this… Read More

  • Bio
    Illumina wants to sequence your whole genome for $100

    Illumina wants to sequence your whole genome for $100

    The first sequencing of the whole human genome in 2003 cost roughly $2.7 billion, but DNA sequencing giant Illumina has now unveiled a new machine that the company says is “expected one day” to order up your whole genome for less than $100. Illumina’s CEO Francis deSouza showed off the machine, called the NovaSeq, onstage at the JP Morgan Healthcare Conference in downtown… Read More

  • Bio
    Move over Cas9, CRISPR-Cas3 might hold the key to solving the antibiotics crisis

    Move over Cas9, CRISPR-Cas3 might hold the key to solving the antibiotics crisis

    Researchers at North Carolina-based Locus Biosciences think they have a potential cure for antibiotic resistance using CRISPR’s lesser-known Cas3 enzyme. Most of the interest in CRISPR technology centers around the enzyme Cas9, which acts as a type of genetic scissors, allowing scientists to snip out, edit and replace DNA at certain intervals along the genome. However, Cas3 goes beyond… Read More

  • Bio
    Chinese scientists CRISPR a human for the first time

    Chinese scientists CRISPR a human for the first time

    A group of Chinese scientists injected a human being with cells genetically edited using CRISPR-Cas9 technology. This is the first time CRISPR has been used on a fully formed adult human and it’s encouraged a biomedical battle between China and the United States. The scientists from China are hoping the genetically edited cells will help their patient fend off a virulent type of… Read More

  • Bio
    Oral arguments for who owns CRISPR-Cas9 start next month

    Oral arguments for who owns CRISPR-Cas9 start next month

    The date has been set for oral arguments to begin over who owns the patent rights to the gene-editing wonder CRISPR-Cas9. Berkeley’s Jennifer Doudna and her colleague from the Max Planck Institute Emmanuelle Charpentier head to court on December 6th to face off against MIT’s Feng Zhang and present their argument before three US Patent and Trademark Office judges on why… Read More